HIV and Substance Use in Latin America: A Scoping Review.

Autor: Huff HV; Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.; School of Public Health, Universidad Peruana Cayetano Heredia, Av. Honorio Delgado 430, San Martin de Porres, Lima 15102, Peru., Carcamo PM; School of Public Health, Universidad Peruana Cayetano Heredia, Av. Honorio Delgado 430, San Martin de Porres, Lima 15102, Peru., Diaz MM; Department of Neurology, University of North Carolina at Chapel Hill, 170 Manning Drive, Campus Box 7025, Chapel Hill, NC 27599, USA., Conklin JL; Health Sciences Library, University of North Carolina at Chapel Hill, 335 South Columbia Street, Campus Box 7585, Chapel Hill, NC 27599, USA., Salvatierra J; University Library Office, Universidad Peruana Cayetano Heredia, Av. Honorio Delgado 430, San Martin de Porres, Lima 15102, Peru., Aponte R; University Library Office, Universidad Peruana Cayetano Heredia, Av. Honorio Delgado 430, San Martin de Porres, Lima 15102, Peru., Garcia PJ; School of Public Health, Universidad Peruana Cayetano Heredia, Av. Honorio Delgado 430, San Martin de Porres, Lima 15102, Peru.
Jazyk: angličtina
Zdroj: International journal of environmental research and public health [Int J Environ Res Public Health] 2022 Jun 12; Vol. 19 (12). Date of Electronic Publication: 2022 Jun 12.
DOI: 10.3390/ijerph19127198
Abstrakt: This scoping review aims to explore the interplay between substance use (SU) and HIV in Latin America (LA). Database searches yielded 3481 references; 196 were included. HIV prevalence among people who used substances (PWUS) ranged from 2.8-15.2%. SU definitions were variable throughout studies, and thus data were not easily comparable. In 2019, only 2% of new HIV infections were attributed to injection drug use (IDU) in LA. Factors associated with HIV among PWUS included being female, IDU and homelessness, and PWUS were likely to engage in risky sexual behaviors, start antiretroviral treatment late, have poor adherence, have treatment failure, be lost to follow-up, have comorbidities, and experience higher mortality rates and lower quality of life, as has been reported in PLWH with SU in other regions. Five intervention studies were identified, and only one was effective at reducing HIV incidence in PWUS. Interventions in other regions have varying success depending on context-specific characteristics, highlighting the need to conduct more research in the LA region. Though progress has been made in establishing SU as a major concern in people living with HIV (PLWH), much more is yet to be done to reduce the burden of HIV and SU in LA.
Databáze: MEDLINE